Episode 461: A New Disease-Modifying Therapy Has Been Submitted for FDA Approval with Dr. Jiwon Oh

A short while ago, we shared very positive results from the Phase 3 clinical trials for fenebrutinib in both relapsing-remitting and primary progressive MS. Those results have been submitted to the FDA for approval.

This week, Dr. Jiwon Oh, the principal investigator in one of the Phase 3 trials for fenebrutinib, walks us through these positive results and explains what makes fenebrutinib a different kind of disease-modifying therapy and who might benefit most from it.

We're also talking about the European approval of Cenrifki (Tolebrutinib) to treat nonrelapsing secondary progressive MS, and we'll share our perspective on why the FDA should have -- and should still -- approve this DMT in the U.S.

We'll tell you about two studies funded by the National MS Society that will focus on identifying links between menopause and MS.

We'll share some sobering news about healthcare affordability in America.

And we'll share some good news from the U.S. House Appropriations Committee, along with an opportunity for you to spend just 5 minutes doing some important advocacy work.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: Fenebrutinib has been submitted to the FDA for approval :22

Cenrifki (Tolebrutinib) approved in Europe for Nonrelapsing Secondary Progressive MS 1:09

National MS Society funds two studies to identify links between menopause and MS 4:19

Healthcare has become unaffordable for the majority of Americans 8:23

The U.S. House Appropriations Committee has approved $20 million in funding for the MS Research Program 11:57

Dr. Jiwon Oh explains why Fenebrutinib is a different kind of disease-modifying therapy, and who may benefit from it 15:36

Share this episode 32:22

Next week 32:43

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/461

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: jon@realtalkms.com
Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes at www.RealTalkMS.com

PHASE 3 CLINICAL TRIAL: Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
https://www.nejm.org/doi/abs/10.1056/NEJMoa2415988

VIDEO: Principal Investigator Dr. Robert Fox Discusses the Phase 3 clinical trial for Tolebrutinib in Nonrelapsing Secondary Progressive MS
https://www.youtube.com/watch?v=tJQ93qdlXrU

GALLUP POLL: U.S. Adults' Ability to Afford Healthcare at a Five-Year Low
https://news.gallup.com/poll/710942/adults-ability-afford-healthcare-five-year-low.aspx

JOIN: The RealTalk MS Facebook Group
https://facebook.com/groups/realtalkms

REVIEW: Give RealTalk MS a rating and review
http://www.realtalkms.com/review

Follow RealTalk MS on X, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 461
Guest: Dr. Jiwon Oh

Privacy Policy